SMN2 copy numbers, despite currently being the main determinant for therapeutic decisions in SMA, hold limited prognostic value regarding disease progression and treatment response, are often difficult to quantify, and have shown inconsistencies between predicted and observed phenotypic outcomes, especially for individuals harboring three copies [25,26]. Here, SMN2 is linked to proximal spinal muscular atrophy.